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ABSTRACT
Objective To characterise changes in selected
haematological parameters following once-daily oral
baricitinib dosing.
Methods Data were pooled from eight randomised clinical
trials (four phase 3, three phase 2, one phase 1b) and one
long-term extension. Changes in haematological parameters
were evaluated up to 128 weeks (N=2387); overall safety
of baricitinib was assessed up to 6 years (N=3492).
Results Mean absolute neutrophil counts decreased
(−1.36×109/L) within 1 month, followed by
stabilisation within the normal reference range through
week 128. The incidence of serious infections was not
elevated in patients with neutropenia during the
24-week placebo-controlled period. Mean lymphocyte
counts increased (+0.30×109/L) within 1 month, then
decreased to baseline (weeks 12–24). Mean platelet
counts increased at week 2 (+51×109/L), then
decreased towards baseline. Overall, mean
haemoglobin concentrations decreased (−0.12 mmol/L),
then returned to baseline; however, reduced
baseline haemoglobin concentrations observed in the
highest baseline high-sensitivity C reactive protein
quartile increased over time. Permanent drug
discontinuation occurred due to laboratory
abnormalities related to neutrophil count in 8 (0.2%),
lymphocyte counts in 6 (0.2%), platelet counts in
8 (0.2%), and haemoglobin levels in 16 (0.5%) of all
baricitinib-treated patients (N=3492 with 7993 total
person-years of exposure).
Conclusions Moderate decreases in neutrophils were
seen during baricitinib treatment; however, serious infection
was uncommon in patients with neutropenia. Transient
increases were observed in lymphocytes and platelets,
which returned to baseline over time. Changes in
haemoglobin concentration were generally small.
Haematological abnormalities seldom led to drug
discontinuation.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflam-
matory disease characterised by synovitis,
progressive damage to appendicular joints
and variable extra-articular manifestations.
To cite: Kay J, Harigai M,




in patients with rheumatoid




► Supplemental material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/rmdo
pen-2020-001370).
Received 18 June 2020
Revised 28 August 2020
Accepted 22 September 2020
© Author(s) (or their
employer(s)) 2020. Re-use
permitted under CC BY-NC. No
commercial re-use. See rights
and permissions. Published
by BMJ.






What is already known about this subject?
► Baricitinib inhibits JAK2-mediated signal
transduction, including that through the
erythropoietin receptor which mediates erythrocyte
production.
What does this study add?
► This study reports changes in haematological
parameters that occurred during the first
19 months of treatment across all studies of
baricitinib conducted in patients with rheumatoid
arthritis.
► Baricitinib treatment was associated with decreases
in neutrophils that were not associated with severe
infections and with transient increases in
lymphocytes and platelets, which usually returned
to baseline levels and remained stable up to
128 weeks of treatment.
► Changes in haemoglobin were generally small-to-
moderate, and mostly reversible. Haematological
abnormalities infrequently resulted in permanent
discontinuation of therapy.
How might this impact on clinical practice?
► Characterisation of the impact of baricitinib
treatment on haematological parameters
contributes to understanding the relative risk and
benefits of its use in patients with rheumatoid
arthritis.
Rheumatoid arthritis
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Medications used to treat RA include conventional
synthetic disease-modifying antirheumatic drugs
(csDMARDs), biological DMARDs (bDMARDs) and tar-
geted synthetic DMARDs (tsDMARDs). However, in clin-
ical practice, despite long-term treatment with
combinations of csDMARDs and bDMARDs, somepatients
with RA do not achieve low disease activity or remission.1
An increased incidence of haematological abnormal-
ities, such as neutropenia, lymphopenia, thrombocytope-
nia and anaemia, has been observed in patients with
RA.2–6 Many drugs used to treat RA may themselves be
associated with haematological abnormalities, through
differing mechanisms depending upon the drug
class.7–11 Additionally, reduction of inflammation with
drug treatment has been associated with improvement
in anaemia and other haematological abnormalities.11–14
Janus kinase (JAK) inhibitors target cytokine signalling
pathways implicated in RA pathogenesis.15 16 In phase 3
clinical trials, treatment with baricitinib, an oral JAK1/
JAK2 inhibitor, has improved signs and symptoms of RA,
including preventing joint damage and preserving physi-
cal function.17–20 Because baricitinib inhibits JAK2-
mediated signalling and erythropoietin stimulates erythro-
cyte production through JAK2 signalling, haemoglobin
and other haematological parameters were of particular
interest during the clinical development of baricitinib.
Here we report changes in key haematological parameters
that were observed during clinical trials of baricitinib in
patients with RA and discuss their clinical relevance.
METHODS
Study design and patients
Data were pooled from eight randomised clinical trials
(four phase 3; three phase 2; one phase 1b) and one
ongoing 104-week long-term extension (LTE). Studies
included in one or more analyses are described in table 1.
Patients were aged ≥18 years and had moderate-to-severely
active RA. Key exclusion criteria included haemoglobin
<10.0 g/dL (6.1 mmol/L); absolute neutrophil count
(ANC) <1.2×109/L; lymphocyte count <0.75×109/L; and
platelet count <100×109/L. Study drug was discontinued
temporarily if a patient’s laboratory results included ANC
<1.0×109/L; lymphocyte count <0.5×109/L; platelet count
<75×109/L; or haemoglobin <8.0 g/dL.
Statistical analyses
A description of the data sets and listing of the analyses in
which they were used is presented in table 2. While collec-
tion of data for most endpoints (adverse events (AEs),
haematological laboratory values, shifts in categorical
classification of haematological laboratory values, and
temporary and permanent discontinuation due to labora-
tory abnormalities) was prespecified in each protocol,
combined and subgroup analyses were performed on
a post hoc basis. The analyses of erythropoietin, reticulo-
cyte count, red blood cell count, and total iron and TIBC
in the JADN study were prespecified exploratory analyses.
Baseline data were summarised as mean (SD) for con-
tinuous variables and n (%) for categorical variables.
Laboratory values over time (neutrophils, lymphocytes
and platelets) were shown as mean and SD. Changes
from baseline over time (haemoglobin) were shown as
mean and SE. All analyses used data as observed (no
imputation of missing data) with the exception of the
analysis of mean neutrophil count by change in high-
sensitivity C reactive protein (hsCRP) categories (online
supplemental figure 1), which usedmodified last observa-
tion carried forward imputation. For change in mean
platelet count and mean platelet volume (MPV) (online
supplemental figure 3), data are shown for patients
receiving baricitinib 4 mg with baseline and on-
treatment count or volume data >0 at a given time
point, censored at rescue.
Assessments
Neutrophil counts, lymphocyte counts, haemoglobin and
platelet counts were assessed in blood samples obtained
at baseline, during randomised treatment up to 24 weeks,
and throughout the LTE. During placebo-controlled,
randomised treatment, samples were collected at study
weeks 2, 4, 8, 12, 14 (except in the JADA study), 16, 20,
and 24. Sampling at later time points differed between
studies; for data points including data obtained at differ-
ent specified study weeks, the range of weeks during
which the samples were collected is indicated on the
horizontal axis (eg, 48–52 weeks). Neutrophil and lym-
phocyte counts were categorised by Common Terminol-
ogy Criteria for Adverse Events (CTCAE) Grade.24
MedDRA-preferred terms for AEs counted as related to
particular cell types or haemoglobin were as follows: for
neutrophils, ‘neutropenia’, ‘neutrophil count
decreased’, ‘febrile neutropenia’ and ‘neutrophilia’; for
lymphocytes, ‘lymphopenia’ and ‘lymphocyte decreased’;
for platelets, ‘thrombocytosis’, ‘thrombocytopenia’ and
‘platelet count decreased’; for haemoglobin, ‘anaemia’
and ‘haemoglobin decreased’.
Haemoglobin concentrations were categorised as treat-
ment-emergent abnormally low and/or below the gen-
der-adjusted lower limit of normal (gaLLN) based on
the following cut-offs: <7.2 mmol/L (11.6 g/dL) for
women <59 years and <7.14 mmol/L (11.5 g/dL) for
women ≥59 years; <7.88 mmol/L (12.7 g/dL) for men
<59 years and <7.76 mmol/L (12.5 g/dL) for men
≥59 years. Treatment-emergent abnormally low haemo-
globin was also separately characterised as shifts from
baseline CTCAE Grade <2 to post-baseline Grade ≥2 and
from baseline Grade <3 to post-baseline Grade ≥3.24
Reversibility was evaluated in a subgroup of patients
(see table 2) who discontinued treatment by week 24
and had data available from baseline, last visit and post-
treatment assessments. For the analysis of platelet count
shifts on treatment (online supplemental table 2),
denominators were the number of patients at risk for
the shift in each treatment group, which could vary
since not all analytes or the same methods were used in
RMD Open
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every study. Anaemia status at baseline by background
medications was assessed in the combined randomised
populations of studies JADV and JADX, which both
required that patients had previously received csDMARDs
or methotrexate (MTX) (see table 1).
Safety assessments included reports of potentially rele-
vant treatment-emergent AEs, serious AEs, and tempor-
ary and permanent treatment discontinuations.
RESULTS
Patients
Data were analysed from 3492 treated patients with up to
7993 patient-years of exposure as of 1 April 2017. Patient
demographics, including age, duration of RA, and corti-
costeroid and MTX use, were similar across treatment
groups in each analysis set (table 3). The mean ages
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Baricitinib 2 mg or
4 mg once daily
*Active RA defined as ≥6/68 tender joints and ≥6/66 swollen joints, CRP ≥3.6 mg/L.
†Concomitant cDMARD required to have been used ≥12 weeks prior to study entry with stable doses for ≥8 weeks prior.
ACPA, anti-citrullinated protein antibodies; bDMARD, biological disease-modifying drug; csDMARD, conventional synthetic disease-modifying
drug; hsCRP, high-sensitivity C reactive protein; HCQ, hydroxychloroquine; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs;
RA, rheumatoid arthritis; RCT, randomised controlled trial; RF, rheumatoid factor; SSZ, sulfasalazine; TNF, tumour necrosis factor.
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Table 2 Data set definitions and list of analyses
24-Week placebo
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the placebo, baricitinib 2 mg and baricitinib 4 mg treat-
ment arms ranged from 52.9 years to 53.7 years, and was
52.9 years in the all Bari-RA set. In the same data sets, the
mean duration of RA since diagnosis was 8.9–9.0 years for
the randomised dose groups and was 7.7 years in the all
Bari-RA set. The majority of patients in each analysis set
were female.
Neutrophils
As shown in figure 1A, baricitinib treatment was associated
with an initial decrease in mean neutrophil count at week
4 (−1.36×109/L below baseline) that stabilised by week 12
(−0.87 ×109/L below baseline) and remained stable within
the normal reference range through week 128. In an
assessment of the reversibility of changes in neutrophils
among all evaluable patients who discontinued treatment
by week 24, the neutrophil count returned to near base-
line levels at the post-treatment visit (figure 1B).
Laboratory abnormality AEs related to neutrophil
counts were reported in 60/3492 patients (1.7%) over
7860 patient-years of exposure. Neutropenia was mostly
of grade 1, occurred infrequently, and an elevated rate of
serious infections was not observed in patients with neu-
tropenia relative to other patients (table 4).
Temporary interruption of study drug administration
due to any neutrophil-related or other haematological
laboratory abnormality occurred infrequently (<1%)
during the randomised treatment phase (table 5). Neu-
trophil count–related laboratory abnormality AEs did
not lead to permanent discontinuation of study drug
during the 24-week placebo-controlled treatment per-
iod for any patients in the placebo or baricitinib 2 mg
or 4 mg treatment groups. Permanent discontinuation
due to neutrophil count-related laboratory abnormal-
ities was reported for 8/3492 patients (0.2%) in the all
Bari-RA set (table 5).
To assess the impact of changes in inflammation on
neutrophil counts, neutrophil counts were summarised
for subgroups of patients with a ≥70% reduction in hsCRP
versus those with an increase or a ≤15% reduction in
hsCRP through 12 weeks of treatment with baricitinib
4 mg in the RA-BEAM study (online supplemental
figure 1). The mean neutrophil count at week 12 for the
≥70% hsCRP reduction subgroup (289/483 patients) was
lower by week 8 than that in patients with an increase or
a ≤15% reduction (78/483), suggesting an association
between greater improvement in inflammation and the
magnitude of decrease in neutrophils.25
Table 2 Continued
24-Week placebo























over time (online sup
plemental figure 7)
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*Data for the follow-up period after treatment discontinuation are included in this analysis.
AEs, adverse events; Bari, baricitinib; cat., category; CTCAE, Common Terminology Criteria for Adverse Events; DVT/PE, deep vein thrombosis/
pulmonary embolism; hsCRP, high-sensitivity C reactive protein, LTE, long-term extension (JADY study); NA, not applicable; RA, rheumatoid
arthritis; RBC, red blood cell.
RMD Open
6 Kay J, et al. RMD Open 2020;6:e001370. doi:10.1136/rmdopen-2020-001370
 on D
ecem










pen: first published as 10.1136/rm






Mean lymphocyte counts increased (+0.30×109/L above
baseline) during the first month of baricitinib
administration, decreased to baseline levels between
weeks 12 and 24 and then remained stable and within
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Figure 2 Mean platelets over time (absolute values) (A) and reversibility assessment for platelets (B).
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(figure 1C). In patients assessed for reversibility of
changes after discontinuation through 24 weeks, lympho-
cyte counts returned to baseline at the post-treatment visit
(figure 1D). Laboratory abnormalities related to lympho-
cyte counts were reported in 133/3492 (3.8%) patients.
Grade 1 lymphopenia was associated with a slightly ele-
vated rate of overall infections in the baricitinib 4 mg
group compared to placebo (81 patients (39.5%) vs 65
patients (27.9%), respectively; table 4). Among all
patients with Grade 1 or higher lymphopenia, 6/284
patients (2.1%) treated with baricitinib 4 mg and 4/349
patients (1.1%) who received placebo developed
a serious infection.
Lymphocyte count–related laboratory abnormality AEs
led to permanent discontinuation during the placebo
controlled treatment period for one patient each in the
placebo (0.1%) and baricitinib 2 mg (0.2%) and bariciti-
nib 4 mg (0.1%) treatment groups. Permanent disconti-
nuation due to lymphocyte count–related laboratory
abnormalities was reported for 6/3492 patients (0.2%)
in the all Bari-RA set (table 5).
Platelets
With baricitinib treatment, mean platelet counts
increased and peaked at week 2 (+51×109/L compared
to baseline), returned towards baseline, and remained
Table 3 Baseline characteristics










Age, years, mean (SD) 52.9 (11.9) 53.7 (12.0) 53.2 (12.0) 52.9 (12.2)
Female, n (%) 862 (80.6) 794 (79.6) 386 (80.6) 2760 (79.0)
Duration of RA*, years, mean (SD) 8.9 (8.4) 8.9 (8.6) 9.0 (8.1) 7.7 (8.2)
Region, n (%)
USA/Canada 240 (22.4) 225 (22.6) 162 (33.8) 840 (24.1)
Central/South America and Mexico 203 (19.0) 197 (19.8) 54 (11.3) 701 (20.1)
Asia (excluding Japan) 84 (7.9) 83 (8.3) 38 (7.9) 226 (6.5)
Japan 156 (14.6) 132 (13.2) 36 (7.5) 514 (14.7)
European Union 263 (24.6) 246 (24.7) 125 (26.1) 783 (22.4)
Rest of the world 124 (11.6) 114 (11.4) 64 (13.4) 428 (12.3)
Background MTX use, yes, n (%) 967 (90.4) 903 (90.6) 386 (80.6) 2661 (76.2)
Corticosteroid use, yes, n (%) 610 (57.0) 538 (54.0) 246 (51.4) 1754 (50.2)
Mean neutrophil count (×109 cells/L) 5.83 6.04 5.73 NA
Mean lymphocyte count (×109 cells/L) 1.82 1.84 1.87 NA
Mean platelet count (×109 cells/L) 289 293 284 NA
*Time from RA diagnosis.
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Figure 3 Mean change from baseline in haemoglobin, weeks 0 to 128.
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stable through week 128 (figure 2). In the subset of
patients who were assessed for reversibility of changes
through 24 weeks, mean platelet counts were somewhat
elevated at the last visit on treatment but returned
towards baseline after treatment discontinuation (barici-
tinib 2 mg: +27×109/L; baricitinib 4 mg: +7×109/L above
baseline).
High platelet counts (>ULN; 394×109/L for age
≥60 years, >400×109/L for age <60 years) were found at
any time during treatment for 16.9% of patients receiving
baricitinib 2 mg and 24.9% of those receiving baricitinib
4 mg versus 9.5% of those receiving placebo; very high
(≥600×109/L) levels were found for 1.5% and 2.3% versus
1.3%, respectively (online supplemental table 1).
Changes in platelet counts were also assessed by base-
line platelet quartile. Following a transient peak at
2 weeks, platelet counts in the highest baseline quartile
decreased slightly and remained below baseline (baseline
mean=411.5×109/L); in the two middle quartiles, platelet
counts remained stable slightly above baseline; and in the
lowest baseline platelet quartile, platelet counts remained
above baseline levels throughout the study (online supple
mental figure 2). In a post hoc analysis of data from RA-
BEAM, a decrease in the MPV was observed concurrently
with the increase in overall mean platelet count (online
supplemental figure 3).
Laboratory abnormality AEs related to platelet counts
were reported in 51/3492 (1.5%) patients. Platelet-
count related laboratory abnormalities led to perma-
nent discontinuation during the placebo controlled
treatment period for one patient (0.2%) in the barici-
tinib 2 mg and one patient (0.1%) in the baricitinib
4 mg treatment group. Permanent discontinuation due
to platelet-related laboratory abnormalities was
reported for 8/3492 patients (0.2%) in the all Bari-
RA set (table 5).
Table 4 Infection by worst CTCAE grade during placebo-controlled period up to week 24


































0 (≥2×109 cells/L) 985
(95.7)
279 (28.3) 16 (1.6) 853
(89.1)
313 (36.7) 13 (1.5) 438
(91.8)
146 (33.3) 6 (1.4)
1 (<2 and ≥1.5×109
cells/L)
34 (3.3) 10 (29.4) 0 74 (7.7) 32 (43.2) 1 (1.4) 22 (4.6) 7 (31.8) 1 (4.5)
2 (<1.5 and
≥1.0×109 cells/L)
9 (0.9) 0 0 27 (2.8) 11 (40.7) 0 14 (2.9) 2 (14.3) 0
3 (<1.0 and
≥0.5×109 cells/L)
1 (0.1) 1 (100.0)† 0 3 (0.3) 1 (33.3)‡ 0 3 (0.6) 1 (33.3) 0




0 (≥1.1×109 cells /L) 710
(67.0)
201 (28.3) 12 (1.7) 704
(71.3)
246 (34.9) 8 (1.1) 349
(73.2)





65 (27.9) 2 (0.9) 205
(20.7)
81 (39.5) 2 (1.0) 87 (18.2) 29 (33.3) 1 (1.1)
2 (<0.8 and
≥0.5×109 cells /L)
103 (9.7) 30 (29.1) 1 (1.0) 71 (7.2) 31 (43.7) 3 (4.2) 35 (7.3) 9 (25.7) 1 (2.9)
3 (<0.5 and
≥0.2×109cells /L)
13 (1.2) 3 (23.1) 1 (7.7)§ 8 (0.8) 4 (50.0) 1 (12.5)¶ 6 (1.3) 2 (33.3) 0
4 (<0.2×109 cells /L) 0 0 0 0 0 0 0 0 0





Only on-treatment laboratory value and events (overall infection, serious infection) are included. Data shown for patients with available post-
baseline assessments.
CTCAE, Common Terminology Criteria for Adverse Events.
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Platelet increases at 2 weeks were not associated with
venous thromboembolic events (VTE).26 Through the
19-month safety update, the highest post-baseline platelet
count was ≥400×109/L for similar proportions of patients
with (15/42, 35.7%) and without (1278/3435, 37.2%)
VTE. Highest post-baseline platelet counts were
≥600×109/L for 3/42 (7.1%) patients with and 123/
3435 (3.6%) patients without VTE (online supplemental
figure 4).
Haemoglobin and related laboratory parameters
Anaemia at screening or baseline
To explore the relationship between age or gender and
disease activity level (represented by hsCRP) with anae-
mia before baricitinib treatment, data were assessed at
screening (for screen failures) or baseline (for rando-
mised patients) using pooled data from two of the phase
3 studies conducted in csDMARDs-experienced patients.
The incidence of anaemia, defined either based on
gaLLN (see the Methods section) or Grade 1
(<6.2 mmol/L [10.0 g/dL]) increased with hsCRP levels
above the upper limit of normal (ULN), and was highest
in patients with hsCRP that was more than 10x the ULN
(online supplemental figure 5).When categorised by age,
differences were found among patients with hsCRP more
than twice theULN, of whom those younger than 45 years
had the highest incidence of haemoglobin below the
gaLLN (online supplemental figure 5).
To assess the incidence of anaemia by background
csDMARDs, baseline data for randomised patients from
the same two phase 3 studies were assessed. At baseline,
anaemia (haemoglobin <gaLLN or anaemia ofmore than
Grade 1) was most commonly present among patients
taking MTX, with or without additional csDMARDs
(online supplemental table 2).
On-treatment analyses
When assessed through up to 128 weeks, small declines
from baseline in mean haemoglobin levels were observed
for both the placebo and baricitinib dose groups at week 2
(placebo −0.15 mmol/L (0.24 g/dL), both baricitinib
doses −0.12 mmol/L (−0.19 g/dL)) and again at week
14 (placebo −0.14mmol/L (−0.23 g/dL), baricitinib 2mg
−0.18mmol/L (−0.29 g/dL) and Bari 4 mg −0.22mmol/L
(−0.35 g/dL)) (figure 3). In patients receiving baricitinib,
mean haemoglobin levels returned to baseline or above by
weeks 48–52.
Changes in haemoglobin concentration over time were
also assessed by quartiles of baseline hsCRP for patients
receiving baricitinib 4 mg (online supplemental figure
6). For the lowest three quartiles of baseline hsCRP, base-
line haemoglobin concentrations were roughly similar,
and transient decreases in mean haemoglobin concentra-
tion with a return to baseline levels were seen. For the
highest baseline hsCRP quartile, which had a lower mean
haemoglobin concentration at baseline, mean haemoglo-
bin concentration decreased transiently and then
increased to levels comparable to the mean baseline hae-
moglobin levels in the other three quartiles. Within the
highest baseline hsCRP quartile, there was a significant
correlation between the increases in haemoglobin over
time and the reduction in hsCRP observed during treat-
ment (change from baseline to week 52, Pearson r=−0.30,
p<0.001; from baseline to week 104, Pearson r=−0.24,
p=0.039).
During the 24-week placebo controlled treatment per-
iod, the incidence of treatment-emergent abnormally low
levels of haemoglobin (see the Methods section) was
comparable between patients receiving placebo (25.8%)
and baricitinib 4 mg (29.3%) and was lower among
patients receiving adalimumab (16.9%, in the RA-BEAM
study). The incidence was also similar across baricitinib
doses when compared in the combined studies that
Table 5 Haematological laboratory abnormality adverse events leading to study drug interruption or permanent discontinua-
tion (on-treatment analysis)
Temporary study drug interruption* Permanent study drug discontinuation
Placebo-controlled period up to
week 24 All Bari-RA
Placebo-controlled period up to

















N 1039 479 966 3369 1070 479 997 3492
Neutrophils 1 (0.1) 0 0 9 (0.3) 0 0 0 8 (0.2)
Lymphocytes 3 (0.3) 2 (0.4) 2 (0.2) 43 (1.3) 1 (0.1) 1 (0.2) 1 (0.1) 6 (0.2)
Platelets 0 0 1 (0.1) 5 (0.1) 0 1 (0.2) 1 (0.1) 8 (0.2)
Haemoglobin 1 (0.1) 0 1 (0.1) 11 (0.3) 0 2 (0.4) 1 (0.1) 16 (0.5)
*Excludes the JADC study as patients could not restart treatment after interruption in JADC.
MedDRA terms for neutrophils, ‘neutropenia,’ ‘neutrophil count decreased’, ‘febrile neutropenia’ and ‘neutrophilia’; for lymphocytes, ‘lym-
phopenia,’ and ‘lymphocyte decreased’; for platelets, ‘thrombocytosis,’ ‘thrombocytopenia’ and ‘platelet count decreased’; for haemoglobin,
‘haemoglobin decreased’ and ‘anaemia’.
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included both baricitinib 2 mg (30.9%) and 4 mg
(35.0%) treatment arms. Similarly, there was a low overall
incidence of treatment-emergent shifts in haemoglobin
from Grade 1 or 2 (haemoglobin ≥4.9 mmol/L [7.9 g/
dL]) to Grade 3 or higher (haemoglobin <4.9 mmol/L)
of 0.2% with placebo, 0.6% with baricitinib 2 mg and
≤0.2% with baricitinib 4 mg.
AEs related to decreased haemoglobin concentrations
were reported in 174/3492 patients (5.0%). Study drug
was discontinued permanently because of decreased hae-
moglobin/anaemia in two patients (0.4%) in the barici-
tinib 2 mg group and one patient (0.1%) in the
baricitinib 4 mg group during the 24 week placebo-
controlled period. Permanent discontinuation due to
decreased haemoglobin/anaemia was reported for 16/
3492 (0.5%) of patients in the all Bari-RA data set
(table 5).
Erythropoietin- and iron-related measures in the JADN study
Erythropoietin concentrations, total iron, total iron-
binding capacity (TIBC), red blood cell count and reti-
culocyte counts accompanying haemoglobin changes
were analysed in the JADN study.27 Dose-dependent
increases in erythropoietin levels were observed over
12 weeks in both the JADN 2 mg and JADN 4 mg barici-
tinib treatment groups (online supplemental figure 7).
Mean red blood cell counts in JADN decreased slightly
and remained stable in patients treated with either bar-
icitinib 2 mg or 4 mg, similar to changes observed in
subjects who received placebo (−1.0% for placebo at
12 weeks, −1.5% for baricitinib 2 mg and −5.0% for bar-
icitinib 4mg). For patients in JADNwhowere treated with
either baricitinib dose, an initial decrease in reticulocyte
count occurred at week 2. Among patients receiving bar-
icitinib 4 mg, this initial decrease was followed by an
increase in reticulocyte count that continued through
week 12. Among patients treated with baricitinib 2 mg,
reticulocyte counts returned to baseline at week 4,
decreased again at week 8 and then returned to near
baseline at week 12.
Statistically significant increases in total iron and TIBC
were observed at week 12 in the JADN study with bariciti-
nib 4 mg treatment, as compared to placebo (online
supplemental figure 8).
DISCUSSION
Changes in haematological parameters, assessed across
the baricitinib development programme, were generally
small-to-moderate in magnitude and were often transi-
ent. The initial decrease in neutrophils is similar to
those reported in studies of other JAK inhibitors for
RA including tofacitinib, upadacitinib and filgotinib.11
28–31 While changes in other haematological parameters
were generally small-to-moderate with all JAK inhibitors,
there are differences in the patterns observed. Bariciti-
nib treatment resulted in initial small transient
increases in platelets, which then decreased towards
baseline and remained within normal range, whereas
treatment with tofacitinib or filgotinib resulted in mod-
erate decreases in platelet counts within normal range,
and upadacitinib had little impact on platelet
counts.31–33 Baricitinib treatment resulted in initial
reductions in haemoglobin within normal range which
subsequently increased above baseline, while upadaciti-
nib treatment had little impact on haemoglobin.33 Fil-
gotinib treatment resulted in dose-dependent increases
in haemoglobin, which plateaued after 12 weeks,31 and
tofactinib treatment resulted in increases in haemoglo-
bin, which plateaued after 12 months but were not
dose-dependent.11
Serious infections, including tuberculosis, bacterial,
invasive fungal, viral and other opportunistic infections,
have been observed with JAK inhibitor use.34 While an
increase in overall infections was observed among
patients treated with baricitinib 4 mg, rates of serious
infections (those resulting in hospitalisation, death or
use of intravenous antibiotics) were similar to those in
the placebo-treated groups.35 In the present study, lym-
phopenia was associated with a slightly higher rate of
overall infection among patients treated with baricitinib
4 mg compared with that among patients receiving pla-
cebo, but serious infections were uncommon in patients
with lymphopenia in both the placebo and in the barici-
tinib 2 mg and 4 mg treatment groups. A decrease in
levels of neutrophils was observed with baricitinib dosing;
however, serious infections were uncommon in patients
with neutropenia, occurring in only one patient each
(both with Grade 1 neutropenia) in the baricitinib 2 mg
and 4 mg treatment arms. In RA-BEAM, a similar pattern
of change in neutrophil count was observed in patients
treated with baricitinib and adalimumab through
52 weeks.18
In the analysis of platelet counts over time, baricitinib
(2mg and 4mg) was associated with transient increases in
the mean platelet count at week 2, which subsequently
remained slightly above baseline. In the exploratory ana-
lysis of patients treated with baricitinib 4mg in RA-BEAM,
a low MPV was observed,36 consistent with the hypothesis
that reduced platelet clearance is the primary mechanism
by which the platelet count increases. Reduced rates of
platelet clearance would result in persistence of older,
smaller platelets in the circulation and thus a lower
MPV. Because older, smaller platelets may contain fewer
granules, express fewer adhesion molecules on their sur-
face, and activate more slowly,37 38 they would be
expected to cause fewer VTE than larger platelets.39
Although in the overall dataset a highest post-baseline
platelet count ≥600×109/L was observed more frequently
in patients who had VTEs versus those who did not (3/42
(7.1%) vs 123/3435 (3.6%, respectively)), interpretation
of this finding is limited by its low overall incidence.
Baricitinib was associated with early, small decreases
from baseline in mean haemoglobin concentrations dur-
ing the placebo-controlled periods, which returned
towards baseline levels with extended treatment. The
Rheumatoid arthritis
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observed decreases in haemoglobin levels were seldom
considered to be clinically relevant, since permanent
drug discontinuation due to anaemia occurred infre-
quently. The initial reduction of haemoglobin, followed
by subsequent increase towards baseline likely resulted
from JAK2 inhibition, by decreasing erythropoietin signal
transduction, while also reducing concentrations of
proinflammatory cytokines, such as interleukin (IL)-6,
and signal transduction through the IL-6 receptor, result-
ing in a diminished inhibitory effect on erythropoiesis.40
Patients in the highest baseline hsCRP quartile, with
the highest burden of inflammation, had lower baseline
haemoglobin concentrations that increased with bariciti-
nib treatment. This increase in haemoglobin during bar-
icitinib treatment correlated significantly with the
decrease in hsCRP in those patients whose baseline
hsCRP was in the highest quartile. IL-6 induces produc-
tion of acute phase reactants, such as CRP and
hepcidin.41 42 Hepcidin regulates iron homoeostasis,
inducing inhibition of intestinal iron reabsorption and
ferroportin-dependent iron mobilisation from
macrophages.42 Increases in haemoglobin in patients
with RA treated with the anti-IL-6 receptor antibody toci-
lizumab are associated with the reversal of iron sequestra-
tion by hepcidin.43 By inhibiting IL-6 receptor
signalling,44 baricitinib may also facilitate iron mobilisa-
tion. Our observation of increased iron in the JADN study
supports the hypothesis that reduction in proinflamma-
tory cytokine receptor signalling through JAK1 inhibition
is a possible mechanism for the improvements in haemo-
globin concentrations observed with baricitinib treat-
ment. These mechanisms may account for the
observation that neither frequency nor severity of anae-
mia increased with long-term baricitinib use.
This descriptive study using post hoc analyses has lim-
itations. Across the studies, entry criteria limited enrol-
ment of patients with low disease activity. In addition,
patients with haemoglobin <10 g/dL were excluded
from participation, as were those identified by site inves-
tigators as having other significant comorbidities. The
absence of such subjects from these clinical trials may
limit the generalisability of the results. The lack of data
on comorbidities, and the exclusion from randomised
clinical trials of patients with certain comorbidities that
otherwise are commonly seen in patients with RA in clin-
ical practice and which might impact haematological
parameters are limitations of this study. Finally, analyses
of erythropoietin, reticulocytes, total iron and TIBC were
derived from a single study in Japanese patients (JADN);
findings might differ in other populations.
In summary, baricitinib treatment was associated with
moderate decreases in neutrophils, and with transient
increases in lymphocytes and platelets, which usually
returned to baseline levels and remained stable up to
128 weeks. Changes in haemoglobin were generally small-
to-moderate and mostly reversible. Changes in haemato-
logical parameters seldom resulted in permanent discon-
tinuation of therapy.
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